Related Experiment Video
Updated: Jun 16, 2026
08:34
Generation of Human Kidney Tubuloids from Tissue and Urine
Published on: April 16, 2021
5.5K
Kidney Organoids in Drug Development: Integrating Technological Advances and Standardization for Effective
Helen Kearney1, Silvia M Mihăilă2, Lorenzo Moroni1
1MERLN Institute for Technology-Inspired Regenerative Medicine, Complex Tissue Regeneration Department, Maastricht University, Maastricht, 6229 ER, the Netherlands.
Advanced Healthcare Materials
|December 18, 2025
Summary
Kidney organoids show promise for drug development but need standardization. Technological advances are improving these models for reliable preclinical testing and regulatory use.
Area of Science:
- Biomedical Engineering
- Developmental Biology
- Toxicology
Background:
- Kidney organoids offer in vitro models for human kidney development and nephrotoxicity.
- Current limitations include maturation, reproducibility, and scalability, hindering drug development applications.
Purpose of the Study:
- To review technological advancements enhancing kidney organoid models.
- To emphasize necessary steps for integrating these models into preclinical drug testing.
- To highlight the importance of standardization for reliable implementation.
Main Methods:
- Review of recent advances in differentiation protocols and biomaterials.
- Exploration of enabling technologies like bioprinting, organ-on-chip systems, and cell sorting.
- Discussion on the need for standardization in organoid differentiation, imaging, and analysis.
Main Results:
- Technological progress is addressing challenges in kidney organoid maturation and scalability.
- Bioprinting, organ-on-chip, and cell sorting technologies are improving organoid models.
- Standardization is crucial for effective implementation and regulatory acceptance.
Conclusions:
- Kidney organoids are advancing as valuable tools for studying kidney development and toxicity.
- Further standardization is essential for their reliable integration into drug development pipelines.
- Standardized kidney organoids can become dependable tools for future preclinical testing.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:10In Vitro Drug Release Testing: Overview, Development and Validation
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
01:24Dosage Regimen: Individualization
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.